<DOC>
	<DOCNO>NCT02363361</DOCNO>
	<brief_summary>This phase II , single center , open-label , non randomize clinical study assess uptake , safety tolerability Imatinib acute Cervical Spinal Cord Injury patient . The aim determine Imatinib reach sufficient blood level give patient cervical spinal cord injury , via gastric feed tube , also evaluate safety tolerability drug treatment .</brief_summary>
	<brief_title>Treatment Cervical Spinal Cord Injury With Imatinib - Safety Feasibility Study</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Men woman age 1880 year 2 . Clinical sign cervical spinal cord injury due trauma . 3 . In otherwise good health condition determine past medical history , physical examination , laboratory test vital sign 4 . Patient conscious orient x 4 ( regard date/time , localisation , situation personal detail ) , high level consciousness , i.e . Glasgow Coma Scale &gt; 14 , assess competent give inform consent . 1 . Diabetes ( type I II ) 2 . Ongoing cancer treatment 3 . Known allergy study drug Imatinib excipients 4 . On current therapy drug may interfere Imatinib , ( e.g . paracetamol , ketoconazole , itraconazole , erythromycin , clarithromycin , dexamethasone , phenytoin , carbamazepine , rifampicin , phenobarbital , fosphenytoin , primidon , Hypericum perforatum ) . 5 . Female subject lactate positive pregnancy test 6 . Known liver kidney disease 7 . Any relevant surgical medical condition opinion investigator may interfere conduct study scientific result . This include hemorrhagic condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>